Impact Factor 2020: 1.226 (@Clarivate Analytics)
5-Year Impact Factor: 2.285 (@Clarivate Analytics)
Immediacy Index: 2.645
  • Users Online: 171
  • Print this page
  • Email this page

    Article Cited by others

ORIGINAL ARTICLE

Long-term safety follow-up of children from a randomized—controlled phase II b proof—of—concept efficacy study of the live, attenuated, tetravalent dengue vaccine (CYD—TDV) in Thailand

Limkittikul Kriengsak, Hattasingh Weerawan, Chansinghakul Danaya, Sabchareon Arunee, Dulyachai Wut, Frago Carina, Wartel T Anh, Langevin Edith, Gailhardou Sophia, Bouckenooghe Alain

Year : 2019| Volume: 12| Issue : 9 | Page no: 396-403

   This article has been cited by
 
1 Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
Rémi Forrat,Gustavo H Dayan,Carlos A DiazGranados,Matthew Bonaparte,Thelma Laot,Maria Rosario Capeding,Leilani Sanchez,Diana Leticia Coronel,Humberto Reynales,Danaya Chansinghakul,Sri Rezeki S Hadinegoro,Ana Paula Perroud,Carina Frago,Betzana Zambrano,Tifany Machabert,Yukun Wu,Alexander Luedtke,Brenda Price,Claire Vigne,Owen Haney,Stephen J Savarino,Alain Bouckenooghe,Fernando Noriega
Clinical Infectious Diseases. 2021;
[Pubmed]  [Google Scholar] [DOI]
2 Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9–50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study
Diana Leticia Coronel-MartÍnez,Juliana Park,Eduardo López-Medina,María Rosario Capeding,Andrés Angelo Cadena Bonfanti,María Cecilia Montalbán,Isabel Ramírez,María Liza Antoinette Gonzales,Carlos A DiazGranados,Betzana Zambrano,Gustavo Dayan,Stephen Savarino,Zhenghong Chen,Hao Wang,Sunny Sun,Matthew Bonaparte,Andrey Rojas,Jenny Carolina Ramírez,Mae Ann Verdan,Fernando Noriega
The Lancet Infectious Diseases. 2020;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article